Literature DB >> 7520352

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.

C Mettlin1, P J Littrup, R A Kane, G P Murphy, F Lee, A Chesley, R Badalament, F K Mostofi.   

Abstract

BACKGROUND: Different indexes that may enhance the early detection capability of prostate specific antigen (PSA) have been proposed. In addition to the indexes relating to the normal PSA level, there are data suggesting the usefulness of the PSA level relative to prostate gland volume (PSA density), age-referenced PSA level, and PSA change. Little research comparing the sensitivity and specificity of these measures in the same population has been reported.
METHODS: All subjects were participants in the American Cancer Society National Prostate Cancer Detection Project. Specificity was studied in 2011 men without prostate cancer, and sensitivity was determined for 171 men with prostate cancer.
RESULTS: Prostate specific antigen change showed the highest specificity (96.4%), and PSA density the lowest (85.3%). The most sensitive index was PSA density, which was positive for 74.7% of the 171 cases of known cancer. A PSA change of more than 0.75 ng/ml per year was the least sensitive index (54.8%). Sensitivity and specificity varied in a narrow range. Improved performance in specificity was achieved only with the loss of sensitivity.
CONCLUSIONS: None of the alternative indexes commonly used in general early detection practice demonstrated particular advantage when compared with the normal PSA concentration, defined as no more than 4.0 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520352     DOI: 10.1002/1097-0142(19940901)74:5<1615::aid-cncr2820740520>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml.

Authors:  Shingo Yamamoto; Takuo Maruyama; Nobuyuki Kondoh; Michio Nojima; Hidekazu Takiuchi; Seiichi Hirota; Hiroki Shima
Journal:  Int Urol Nephrol       Date:  2007-07-06       Impact factor: 2.370

3.  Latest tests for prostatic neoplasia.

Authors:  W J Marshall
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

Review 4.  [Oncology '96].

Authors:  F Hartmann; M Pfreundschuh
Journal:  Med Klin (Munich)       Date:  1997-02-15

5.  Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.

Authors:  Mohammadreza Nowroozi; Mohsen Ayati; Hassan Jamshidian; Amir Arbab; Hamidreza Ghorbani; Erfan Amini; Hassan Hakima; Sohrab Salehi; Alireza Ghadian
Journal:  Nephrourol Mon       Date:  2015-03-20

6.  Point-of-care rare cell cancer diagnostics.

Authors:  David Issadore
Journal:  Methods Mol Biol       Date:  2015

7.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.

Authors:  Helen M Heneghan; Nicola Miller; Ronan Kelly; John Newell; Michael J Kerin
Journal:  Oncologist       Date:  2010-06-24

8.  Current usefulness of free/total PSA ratio in the diagnosis of prostate cancer at an early stage.

Authors:  Christian Pfister; Jean-Pierre Basuyau
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

9.  Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery.

Authors:  Tzu-Chiao Chao; Nicole Hansmeier; Rolf U Halden
Journal:  J Proteomics       Date:  2010-04-22       Impact factor: 4.044

10.  Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer.

Authors:  Rui-chao Zeng; Wei Zhang; Xing-qiang Yan; Zhi-qiang Ye; En-dong Chen; Du-ping Huang; Xiao-hua Zhang; Guan-li Huang
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.